Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 2
1951 4
1952 1
1954 2
1955 1
1958 1
1959 1
1961 1
1962 2
1963 4
1964 4
1965 6
1966 6
1968 4
1969 3
1970 4
1971 1
1972 5
1973 4
1974 5
1975 6
1976 8
1977 7
1978 4
1979 14
1980 9
1981 5
1982 5
1983 7
1984 7
1985 7
1986 10
1987 10
1988 8
1989 5
1990 7
1991 12
1992 11
1993 14
1994 16
1995 21
1996 24
1997 18
1998 23
1999 29
2000 35
2001 70
2002 60
2003 64
2004 64
2005 94
2006 111
2007 92
2008 128
2009 120
2010 152
2011 196
2012 213
2013 196
2014 255
2015 313
2016 295
2017 327
2018 361
2019 410
2020 467
2021 514
2022 576
2023 584
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

5,441 results

Results by year

Filters applied: . Clear all
Page 1
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, Xu X, Li X, Xu F, Fang Y, Yang R, Yu G, Gong Y, Zhao J, Fan Y, Liu Q, Cao L, Yao Y, Liu Y, Li X, Wu J, He Z, Lu K, Jiang L, Hu C, Zhao W, Zhang B, Shi W, Zhang X, Cheng Y; CAPSTONE-1 Study Group. Wang J, et al. Among authors: lu k. Lancet Oncol. 2022 Jun;23(6):739-747. doi: 10.1016/S1470-2045(22)00224-8. Epub 2022 May 13. Lancet Oncol. 2022. PMID: 35576956 Clinical Trial.
Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial.
Pozo-Rosich P, Ailani J, Ashina M, Goadsby PJ, Lipton RB, Reuter U, Guo H, Schwefel B, Lu K, Boinpally R, Miceli R, De Abreu Ferreira R, McCusker E, Yu SY, Severt L, Finnegan M, Trugman JM. Pozo-Rosich P, et al. Among authors: lu k. Lancet. 2023 Sep 2;402(10404):775-785. doi: 10.1016/S0140-6736(23)01049-8. Epub 2023 Jul 26. Lancet. 2023. PMID: 37516125 Clinical Trial.
Ginseng polysaccharides: Potential antitumor agents.
Tao R, Lu K, Zong G, Xia Y, Han H, Zhao Y, Wei Z, Lu Y. Tao R, et al. Among authors: lu k. J Ginseng Res. 2023 Jan;47(1):9-22. doi: 10.1016/j.jgr.2022.07.002. Epub 2022 Jul 16. J Ginseng Res. 2023. PMID: 36644386 Free PMC article. Review.
Pathogenic mechanism of Vibrio vulnificus infection.
Lu K, Li Y, Chen R, Yang H, Wang Y, Xiong W, Xu F, Yuan Q, Liang H, Xiao X, Huang R, Chen Z, Tian C, Wang S. Lu K, et al. Future Microbiol. 2023 Apr;18:373-383. doi: 10.2217/fmb-2022-0243. Epub 2023 May 9. Future Microbiol. 2023. PMID: 37158065 Review.
Attention Weighted Local Descriptors.
Wang C, Xu R, Lu K, Xu S, Meng W, Zhang Y, Fan B, Zhang X. Wang C, et al. Among authors: lu k. IEEE Trans Pattern Anal Mach Intell. 2023 Sep;45(9):10632-10649. doi: 10.1109/TPAMI.2023.3266728. Epub 2023 Aug 7. IEEE Trans Pattern Anal Mach Intell. 2023. PMID: 37074894
5,441 results